For me the biggest catalyst would be a partnership with Biogen. This would be the best endorsement of the science I can see and drive the SP way up.
I expect the announcement of a partnership BEFORE the publishing of the possible game changing data.
GLTA and IMHO
The change of rules is perfect for AEMD, similar rules are also now being used in Europe . I hope that the use of those medical devices in a much wider population will also reduce or eliminate those insane sugar pill pivotal trials where half of the patients get a fake treatment. The important thing is that real life experience will clearly show indisputable benefits. As I said all along, the EBOLA scare is opening the door to all kinds of other deadly deceases in which our filter can be used.
HUGE AND OUTRIGHT PERFECT FOR AEMD
AEMD is days away to become a company which is going to be taken seriously in the market place.
I was surprised about this bold large reverse split, but in light of those favorable new rules there is a mighty good chance that institutional investors will see the opportunity in this vastly improved timeline.
The Food and Drug Administration (FDA or the Agency) is introducing a new, voluntary
program for certain medical devices that demonstrate the potential to address unmet medical
needs for life threatening or irreversibly debilitating diseases or conditions and are subject to
premarket approval applications (PMAs) or de novo requests. FDA believes that the “Expedited
Access Pathway for Unmet Medical Needs for Life Threatening or Irreversibly Debilitating
Diseases or Conditions” (“Expedited Access Pathway” or “EAP”) program will help patients
have more timely access to these medical devices by expediting their development, assessment,
and review, while preserving the statutory standard of reasonable assurance of safety and
effectiveness for premarket approval1 and the statutory standards for granting a de novo request2
consistent with the Agency’s statutory mission to protect and promote public health.
In some cases, patients may be willing to assume greater risk for earlier access to a medical
device. This may be particularly true for patients with conditions for which no treatments exist or
those who face serious or life-threatening conditions. FDA must ensure that if access to medical
devices is expedited, FDA is reasonably assured the device is safe and effective. Reducing
premarket data requirements while increasing postmarket requirements for devices subject to a
PMA, when appropriate, can assist FDA in making medical devices available to patients sooner
than if following the traditional premarket review pathway. Devices eligible for this pathway
include new devices and existing devices for which a new indication is sought or when there is a
change or modification in the device that could significantly affect the safety and effectiveness of
I am not trading, but it is clear to me that you are a guy of integrity. Forget red thumps, they have nothing to do with your posts. YAHOO Message boards attract all kind of weirdos and paid bashers who try to get good posters off the MB.
Thanks for your contributions.
Normally the D disappears after 20 trading days. FINRA approves the split, stock starts trading , 20 TRADING days and D falls off.
MAY 16 !!!!!!
Another case how overreaction to a reverse can mean a great buying opportunity. I wonder how many bashers bought at the low after they frightened inexperienced retail investors.
My bet is on Biogen my largest Biotech holding. Bought IDEC for 3 Dollars for those who are familiar with the merger and most successful antibody story so far.
Greetings from a Bavarian living in San Diego. Any penny stock listing is the Wild West of next to no regulation over the counter. Invest at your own risk with an amount you can afford to lose.
I have had good luck with large and small reverse splits lately buying before the intended reverse. Companies seem to have a better understanding now about which reverse will succeed. Getting a SP around 10 Dollars in combination with an up listing has been the most successful way lately.
NVIV executed its reverse today and I am happy with the market response. Like AEMD the up list is pending and should be a booster .
Thanks to the sellers to let me again add to my position of AEMD shares under .20
I think it is UP FROM HERE
Often makes a good buying opportunity in a stock with upward trajectory. As long as there is a real interest from institution to buy shares of the company it is a win situation. This is the only important question you have to ask yourself.
IS THERE REAL INTEREST BY INSTITUTIONS TO BUY THE STOCK ?????
I think the CEO knows and he knows if news are coming which will create this buying interest.
I don't believe he would have done such a drastic reverse without being convinced about this buying interest.
He is not suicidal :-) :-)